Ipsen recruits Steven Hildemann as CMO; Eli Lilly offers two more low-cost insulin options
→ After losing their CEO last month, Ipsen — who’s grappling with an FDA hold after safety concerns emerged from late-stage studies of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
